Daewoong Pharma has announced that Nabota (botulinum toxin type A) has exceeded 1 trillion won (approximately $750 million USD) in cumulative sales, driven primarily by strong domestic performance in South Korea and accelerating international uptake. Nabota represents a third-party botulinum toxin competing against the established Type A franchise (Allergan, Galderma, Revance) in markets where regulatory pathways and reimbursement allow.
Injectables
Daewoong Pharma's Nabota Surpasses 1 Trillion Won in Sales — South Korean Toxin Accelerates Global Expansion
Nabota's domestic milestone signals momentum in international markets as a third-party botulinum toxin alternative.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Nabota has surpassed 1 trillion won in cumulative sales, signaling momentum for a third-party botulinum toxin outside the Allergan-Galderma duopoly.
For U.S. and European practice owners, Nabota's global momentum is worth tracking. The toxin has gained regulatory approval in select markets (South Korea, parts of Asia, and limited European availability) and is pursuing broader international expansion. While Nabota does not yet have FDA approval in the United States, its success in adjacent markets demonstrates that non-Allergan Type A toxins can achieve scale when pricing, distribution, and clinical data align. The competitive pressure on Allergan's toxin pricing and rebate structures could intensify if Nabota gains traction in Europe or secures U.S. approval.
Source: original report ↗
Frequently asked questions
What is Nabota and how does it compare to Botox?
Nabota is a botulinum toxin type A manufactured by South Korean company Daewoong Pharma, competing directly with Botox and other established toxins. It has achieved regulatory approval in South Korea, parts of Asia, and select European markets, but does not yet have FDA approval in the United States. Like other Type A toxins, it works identically for wrinkle reduction and muscle relaxation, with differences primarily in pricing, distribution, and regional availability.
Is Nabota available in the United States?
Nabota does not currently have FDA approval and is not available for clinical use in the U.S. market. It is approved in South Korea, parts of Asia, and has limited availability in select European countries. U.S. practitioners should continue to monitor regulatory developments, as Nabota's success in adjacent markets suggests potential for future American market entry.
How much has Nabota sold globally?
Nabota has exceeded 1 trillion won (approximately $750 million USD) in cumulative sales, with the majority driven by strong domestic performance in South Korea. This milestone demonstrates significant market traction and signals accelerating international uptake, particularly in Asia and Europe.
Could Nabota affect Botox pricing and market competition?
Yes—Nabota's global momentum and success as a non-Allergan Type A toxin could intensify competitive pressure on Allergan's pricing and rebate structures, particularly if Nabota gains traction in Europe or secures U.S. FDA approval. This competitive dynamic may benefit practices through improved pricing leverage and more options for toxin sourcing.
What markets currently offer Nabota?
Nabota is currently approved and available in South Korea (its primary market), select Asian countries, and limited European markets. The company is actively pursuing broader international expansion, but availability remains geographically restricted outside these regions.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.